文献速递骨质疏松与代谢性骨病

英国绝经后女性骨质疏松治疗持续性与依从性研究

Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink.
PubMed 文献 · Osteoporos Int · 2019-11-22

基于英国临床实践研究数据链,纳入2010至2015年间接受至少一次骨质疏松药物处方的50岁以上或早绝经女性共72,256例,评估24个月和5年治疗持续性。结果显示24个月持续性仅31.0%,5年降至13.1%,地诺单抗24个月持续性64%高于口服双膦酸盐28%和静脉双膦酸盐23%。

要点

  • 任何骨质疏松治疗24个月持续性仅31.0%,5年降至13.1%。
  • 地诺单抗24个月持续性64%,高于口服双膦酸盐28%和静脉双膦酸盐23%。
  • 从首次暴露开始评估的初治患者持续性和依从性更高。

核心结论

  • 接受骨质疏松治疗的患者中仅约三分之一在2年后仍持续治疗,需改善持续性尤其是高危患者。

研究设计与样本

  • 基于英国临床实践研究数据链的回顾性队列研究,纳入2010年1月1日至2015年12月31日间接受至少一次骨质疏松药物处方的50岁以上或早绝经女性72,256例。

主要发现

  • 全部患者队列6、12、18、24个月持续性分别为56.1%、43.6%、36.4%、31.0%,3年和5年分别为23.2%和13.1%。
  • 初治患者队列的持续性和依从性普遍高于全部患者队列。
  • 药物特异性分析中,地诺单抗24个月持续性64%,口服双膦酸盐28%,静脉双膦酸盐23%。

临床怎么用

  • 临床应关注骨质疏松治疗的长期持续性,尤其对高危患者需采取措施提高依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Gaining full benefits from osteoporosis medications requires long-term treatment. Investigating the real-world persistence of women receiving osteoporosis medications in the UK, we found that most patients stop treatment within a year. To prevent osteoporotic fragility fractures, long-term treatment persistence must be improved. INTRODUCTION: Persistence with osteoporosis therapies has historically been poor. To treat this chronic and progressive disease, it is essential that patients receive the full benefit of these medications. We estimated persistence and compliance with osteoporosis therapies in a large sample of postmenopausal women in the UK. METHODS: Data were obtained from the Clinical Practice Research Datalink for all women aged 50 years and over or women with early menopause, who received at least one prescription in primary care for any licensed osteoporosis therapy between January 1, 2010 and December 31, 2015. Persistence and compliance at 24 months (primary objective) and at 5 years (exploratory objective) were estimated in three patient cohorts: "All Patients," "Naïve Patients," and "Drug-Specific." RESULTS: The All Patients cohort included 72,256 women. Persistence with any therapy was 56.1%, 43.6%, 36.4%, and 31.0% at 6, 12, 18, and 24 months, respectively, and 23.2% and 13.1% at 3 years and 5 years, respectively. Patients were generally more persistent and compliant if evaluated from their first exposure to osteoporosis therapy (Naïve Patients cohort). In the drug-specific analysis, 64% of patients receiving denosumab (administered subcutaneously every 6 months) were persistent at 24 months compared with 28% and 23% of those taking oral bisphosphonates and intravenous bisphosphonates, respectively. CONCLUSIONS: Only about one in three patients who received osteoporosis therapy continued to be on treatment after 2 years. There is a need to improve persistence with osteoporosis therapy, especially for high-risk patients.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Morley J, Moayyeri A, Ali L, et al. Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int. 2019. PMID: 31758206. doi:10.1007/s00198-019-05228-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。